Khayatan Danial, Lemberg Daniel A, Day Andrew S
Department of Dermatology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Paediatric Gastroenterology, Sydney Children's Hospital, Randwick, Sydney 2031, Australia.
J Clin Med. 2024 Sep 18;13(18):5518. doi: 10.3390/jcm13185518.
Management of ulcerative colitis and Crohn's disease, the main subtypes of inflammatory bowel disease (IBD), focuses on the induction and maintenance of remission. Tacrolimus, a member of a group of drugs termed calcineurin inhibitors, may have a role in the medical management of IBD when given either systemically or topically. This review aimed to evaluate the available data focusing on the use of topical tacrolimus in the management of IBD. Reports of the use of topical tacrolimus in IBD were extracted from databases up to 31 May 2024. Topical tacrolimus therapy appears to have reasonable efficacy in the induction and maintenance of remission in patients with refractory IBD, with an acceptable safety profile. Overall, the available data are supportive of the use of topical tacrolimus in selected patients. Further comparative clinical studies are required to more fully delineate the role of this drug.
溃疡性结肠炎和克罗恩病是炎症性肠病（IBD）的主要亚型，其治疗重点在于诱导和维持缓解。他克莫司是一类称为钙调神经磷酸酶抑制剂的药物成员，全身给药或局部给药时可能在IBD的药物治疗中发挥作用。本综述旨在评估聚焦于局部应用他克莫司治疗IBD的现有数据。截至2024年5月31日，从数据库中提取了关于局部应用他克莫司治疗IBD的报告。局部应用他克莫司治疗似乎在诱导和维持难治性IBD患者缓解方面具有合理疗效，安全性也可接受。总体而言，现有数据支持在特定患者中使用局部他克莫司。需要进一步的比较临床研究来更全面地阐明该药物的作用。
